Anti-Mouse IL-17F Antibody (MM17F8F5.1A9)
Based on 1 Customer Validation
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-17F. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can neutralize IL-17. Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) can be used for the researches of cancer, infection and neurological disease, such as Alzheimer’s disease (AD) and pancreatic cancer.
For research use only. We do not sell to patients.
- Purity : ≥95.0%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Mouse IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
IL-17F
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) (400 μg, i.p., every 3-4 days until 6 weeks) reduces disease burden and pathological fibrosis in pancreatic cancer mice models[2].
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) (200 μg at days −1 and 100 μg every other day thereafter, i.p.) shows anti-infection effect companied with anti-IL-17A (HY-P990222) in S. aureus infected mice models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Alzheimer’s disease mice models[1]
-
Dosage:200 μg for the first day and 100 μg every other day
-
Administration:Intraperitoneally injection, 3 weeks
-
Result:Reduced neutrophil recruitment and proportion of γδ T cells.
Increased proportion of phagocytic microglia.
Reduced IL-17, IL-8 and TGFβ signaling in non-phagocytic microglia and neutrophil degranulation in phagocytic microglia.
Reduced accumulation of neutrophils at the choroid plexus.
Increased immunoreactivity of Clec7a+ neurodegenerative microglia.
-
Animal Model:S. aureus infected mice models[3]
-
Dosage:200 μg at days −1 and 100 μg every other day thereafter
-
Administration:Intraperitoneally injection, companied with anti-IL-17A (HY-P990222)
-
Result:Resulted in statistically increased lesion sizes and in vivo BLI signals.
Gene ID
Accession
Q7TNI7-1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo IL-17F neutralization
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-17F Antibody (MM17F8F5.1A9)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Rosenzweig N, et al. Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease. Nat Med. 2024 Oct;30(10):2990-3003. [Content Brief]
[2]. Hegde S, et al. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell. 2020 Mar 16;37(3):289-307.e9. [Content Brief]
[3]. Marchitto MC, et al. Clonal Vγ6+Vδ4+ T cells promote IL-17-mediated immunity against Staphylococcus aureus skin infection. Proc Natl Acad Sci U S A. 2019 May 28;116(22):10917-10926. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)